Ivonescimab's first marketing application in the United States has been rejected. On November 16, Akeso's stock price plunged more than 20% after the market opened. By 9:40 a.m., the decline had reached 23.03%, leaving the company with a market value of less than HK$60 billion. Ivonescimab is a globally first-in-class PD-1/VEGF bispecific tumor immunotherapy independently developed by Akeso and is one of the most closely watched products in the global innovative drug sector in recent years. Its clinical progress and commercialization results will determine not only whether it can rank among the mainstream first-line treatment regimens for lung cancer worldwide, but also whether the entire PD-1/VEGF bispecific antibody sector can challenge the benchmark position of PD-(L)1 monoclonal antibodies in tumor immunotherapy. The indication rejected in the United States this time was ivonescimab combined with chemotherapy for the treatment of EGFR-mutated non-squamous non-small cell lung cancer that has progressed after third-generation EGFR-TKI therapy.
